Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1/2 Study of VS-6766 + Sotorasib in G12C NSCLC Patients (RAMP203)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05074810
Recruitment Status : Not yet recruiting
First Posted : October 12, 2021
Last Update Posted : October 20, 2021
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Verastem, Inc.

Brief Summary:
This study will assess the safety and efficacy of VS-6766 in combination with sotorasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer KRAS Activating Mutation Drug: VS-6766 and sotorasib Phase 1 Phase 2

Detailed Description:
This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety and tolerability and efficacy of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant NSCLC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 53 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of VS-6766 in Combination With Sotorasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Estimated Study Start Date : December 2021
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : September 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Sotorasib

Arm Intervention/treatment
Experimental: VS-6766+sotorasib
To determine the recommended phase 2 dose (RP2D) for VS 6766 in combination with sotorasib in G12C inhibitor naïve and exposed patients
Drug: VS-6766 and sotorasib
The RP2D of VS-6766 + sotorasib determined in Part A will be used in Part B dose expansion
Other Names:
  • AMG 510
  • LUMAKRAS™

Experimental: VS-6766+sotorasib - G12C inhibitor naïve
To determine the efficacy of the RP2D identified from Part A in G12C inhibitor naïve patients
Drug: VS-6766 and sotorasib
The RP2D of VS-6766 + sotorasib determined in Part A will be used in Part B dose expansion
Other Names:
  • AMG 510
  • LUMAKRAS™

Experimental: VS-6766+sotorasib - G12C inhibitor exposed
To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients
Drug: VS-6766 and sotorasib
The RP2D of VS-6766 + sotorasib determined in Part A will be used in Part B dose expansion
Other Names:
  • AMG 510
  • LUMAKRAS™




Primary Outcome Measures :
  1. Part A: To determine RP2D for VS-6766 in combination with sotorasib [ Time Frame: From start of treatment to confirmation of RP2D; 28 days ]
    Assessment of Dose-limiting toxicities (DLTs)

  2. Part B: To determine the efficacy of the optimal regimen identified from Part A [ Time Frame: From start of treatment to confirmation of response; 16 weeks ]
    Confirmed overall response rate per RECIST 1.1


Secondary Outcome Measures :
  1. To characterize the safety and toxicity profile [ Time Frame: 24 months ]
    Treatment emergent adverse events/ treatment emergent serious adverse events - their frequency, duration and severity, lab parameters, vital signs and ECG changes based on CTCAE

  2. Duration of Response (DOR) [ Time Frame: Time from the first documentation of response to first documentation of progressive disease or death due to any cause, greater than or equal to 6 months ]
    Time of first response to PD as assessed per RECIST 1.1

  3. Disease Control Rate (DCR) [ Time Frame: Greater than or equal to 8 weeks ]
    CR and PR stable disease as assessed per RECIST 1.1

  4. Progression Free Survival (PFS) [ Time Frame: 24 months ]
    From the time of first dose of study intervention to PD or death from any cause

  5. Overall Survival (OS) [ Time Frame: Up to 5 years ]
    From time of first dose of study intervention to death

  6. Plasma Pharmacokinetics (PK) of VS 6766, sotorasib, and relevant metabolites - Tmax [ Time Frame: 10 weeks ]
    time of Maximum concentration (Tmax)

  7. Plasma Pharmacokinetics (PK) of VS 6766, sotorasib, and relevant metabolites -AUC [ Time Frame: 10 weeks ]
    Area under plasma Concentration (AUC) 0 to t

  8. Plasma Pharmacokinetics (PK) of VS 6766, sotorasib, and relevant metabolites half-life [ Time Frame: 10 weeks ]
    concentration Half-life (T1/2)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients ≥ 18 years of age
  • Histologic or cytologic evidence of NSCLC
  • Known G12C KRAS mutation
  • Have not received a KRAS inhibitor to be included in Part A and Part B, Cohort 1
  • Received at least 1 dose of a G12C inhibitor to be included in Part A or Part B Cohort 2
  • Must have received appropriate treatment with at least one prior systemic regimen, but no more than 3 prior regimens, for Stage 3B-C or 4 NSCLC
  • Measurable disease according to RECIST 1.1
  • An Eastern Cooperative Group (ECOG) performance status ≤ 1
  • Adequate organ function
  • Adequate recovery from toxicities related to prior treatments
  • Agreement to use highly effective method of contraceptive

Exclusion Criteria:

  • Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy
  • History of prior malignancy, with the exception of curatively treated malignancies
  • Major surgery within 4 weeks (excluding placement of vascular access)
  • History of treatment with a direct and specific inhibitor of MEK
  • Exposure to strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose and during the course of therapy
  • Symptomatic brain metastases requiring steroids or other local interventions.
  • Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy
  • Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active
  • Active skin disorder that has required systemic therapy within the past year
  • History of rhabdomyolysis
  • Concurrent ocular disorders
  • Concurrent heart disease or severe obstructive pulmonary disease
  • Inability to swallow oral medications
  • Female patients that are pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05074810


Contacts
Layout table for location contacts
Contact: Gloria Patrick 781-469-1594 gpatrick@verastem.com

Sponsors and Collaborators
Verastem, Inc.
Amgen
Investigators
Layout table for investigator information
Study Director: Hagop Youssoufian, MD Verastem Oncology
Layout table for additonal information
Responsible Party: Verastem, Inc.
ClinicalTrials.gov Identifier: NCT05074810    
Other Study ID Numbers: VS-6766-203
First Posted: October 12, 2021    Key Record Dates
Last Update Posted: October 20, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Verastem, Inc.:
NSCLC
KRAS G12C
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms